Showing 3651-3660 of 8876 results for "".
- Arcutis Seeks FDA Greenlight to Expand ZORYVE for Children Under 6https://practicaldermatology.com/news/arcutis-seeks-fda-greenlight-to-expand-zoryve-for-children-under-6/2483230/Arcutis Biotherapeutics has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in children aged 2 to 5, according to
- Study: Azelaic Acid Shows Positive Outcomes in Pregnant Acne Patientshttps://practicaldermatology.com/news/study-azelaic-acid-offers-superior-outcomes-in-pregnant-acne-patients/2483218/New retrospective data on topical therapies for acne vulgaris during pregnancy suggested azelaic acid demonstrated greater efficacy compared to erythromycin or clindamycin. The study, conducted between 2018 and 2022, analyzed
- Analysis: GLP-1 Receptor Agonists Linked with Reduced Surgical/Hospitalization Burden in HShttps://practicaldermatology.com/news/analysis-glp-1-receptor-agonists-reduced-surgical-and-hospitalization-burden-in-hs/2483172/New real-world data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are linked with reduced surgical interventions and hospitalizations in patients with hidradenitis suppurativa (HS). Researchers using real
- Bimekizumab Achieves Dual Clearance of Nail and Skin Psoriasishttps://practicaldermatology.com/news/bimekizumab-achieves-dual-clearance-of-nail-and-skin-psoriasis/2483170/In pooled analyses of phase III and IIIb trials, bimekizumab was associated with significantly higher rates of complete clearance of both skin and nail psoriasis compared to adalimumab, ustekinumab, and secukinumab in patients with moderate-to-severe plaque psorias
- Study: Tralokinumab Demonstrates Durable Response, High Retention in AD Patientshttps://practicaldermatology.com/news/tralokinumab-shows-strong-one-year-results-in-real-world-ad-study/2483171/The long-term use of tralokinumab in adults with moderate-to-severe atopic dermatitis (AD). Over a 52-week period, the IL-13 inhibitor demonstrated clinically meaningful and sustained improvements across multiple outcome measures, with a favorable safety profile and
- Analysis: Global Prevalence of Hidradenitis Suppurativa Higher Than Previously Estimatedhttps://practicaldermatology.com/news/analysis-global-prevalence-of-hidradenitis-suppurativa-higher-than-previously-estimated/2483148/The estimate of the global prevalence of hidradenitis suppurativa (HS) sits at 0.99%, which notably higher than prior global figures, according to a new analysis. The research team compiled data from 25 population-based studies
- JAK Inhibitors Linked to Lower Adjunctive Therapy Use Than Dupilumab in ADhttps://practicaldermatology.com/news/jak-inhibitors-linked-to-lower-adjunctive-therapy-use-than-dupilumab-in-ad/2483122/Patients with atopic dermatitis (AD) treated with oral Janus kinase (JAK) inhibitors used fewer adjunctive therapies over the long term compared to those receiving dupilumab, according to a retrospective study published ahead of print in
- Amarte Relaunches Dermatologist-Formulated Ultra Veil Daily SPF 40https://practicaldermatology.com/news/amarte-relaunches-ultra-veil-daily-spf-40/2483087/Amarte Skin Care has relaunched its flagship sunscreen, ULTRA VEIL® DAILY SPF 40, according to a press release from the manufacturer. The updated product maintains its position as a top-tier hybrid sunscreen, the press release
- Review: Psoriasis May Increase Infection Risk After Hip Arthroplastyhttps://practicaldermatology.com/news/review-psoriasis-may-increase-infection-risk-after-hip-arthroplasty/2483053/Patients with psoriasis undergoing total hip arthroplasty (THA) may face a higher risk of postoperative infection, with evidence regarding total knee arthroplasty (TKA) outcomes remaining inconclusive, according to a new systematic review,
- HS Patients on Adalimumab Face Higher Risk of Serious Infections than PsO Counterpartshttps://practicaldermatology.com/news/hs-patients-on-adalimumab-face-higher-risk-of-serious-infections-than-pso-counterparts/2483028/Patients with hidradenitis suppurativa (HS) initiating adalimumab face a significantly higher risk of serious, noncutaneous infections requiring hospitalization compared with patients with psoriasis, a new cohort study finds.